Varanasi News Magazine

Follicular Lymphoma Market, Epidemiology, and Market Forecast Analysis Report

 Breaking News
  • No posts were found

Follicular Lymphoma Market, Epidemiology, and Market Forecast Analysis Report

April 23
02:14 2021
Follicular Lymphoma Market, Epidemiology, and Market Forecast Analysis Report

DelveInsight Business Research LLP
DelveInsight’s ‘Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

What is Follicular Lymphoma?

Follicular lymphoma, a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs.  

 What are Follicular Lymphoma causes?

Follicular Lymphoma causes are not known. Unlike some cancers, they are not passed down in families. In some cases, radiation or cancer-causing chemicals, or certain infections, may be a cause. But other times there is no known cause.

What are the symptoms of Follicular Lymphoma?

Follicular Lymphoma symptoms include painless swelling of the lymph nodes in your neck, groin, stomach, or armpits, shortness of breath, fatigue, night sweats, and weight loss.

How Follicular Lymphoma affected population?

Follicular Lymphoma Epidemiology

  • According to DelveInsight’s analysis, the total prevalent population of Follicular Lymphoma in seven major markets was 33,363 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
  • Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases.
  • In the US, the Follicular Lymphoma cases were 14,329 in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 cases.

To know more, request sample pages @Follicular Lymphoma Market Landscape

Follicular Lymphoma Market Outlook

 

According to DelveInsight, the Follicular Lymphoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with USD 799 million in 2017, while Spain had the smallest market size of Follicular Lymphoma with USD 56 million in 2017.

What are the present Follicular Lymphoma market drivers?

Changing standards of care, increasing opportunities and family history aims at driving the market growth.

What are the Follicular Lymphoma market barriers?

Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the Follicular Lymphoma Market Growth.

Which are the leading companies in Follicular Lymphoma market?

Key Players such as Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, and others are the leading companies in Follicular Lymphoma market.

Table of contents

1. Key Insights

2. Executive Summary of Follicular Lymphoma

3. SWOT Analysis for Follicular Lymphoma

4. Follicular Lymphoma Market Overview at a Glance

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Country Wise-Epidemiology of Follicular Lymphoma

8. Treatment

9. Guidelines

10. Unmet Needs

11. Organizations contributing toward Follicular Lymphoma

12. Patient Journey

13. Case Reports

14. Marketed Therapies

14.1. Tazverik: Epizyme

14.2. Aliqopa: Bayer Healthcare Pharmaceuticals

14.3. Copiktra: Verastem Oncology

14.4. Zydelig: Gilead Sciences

15. Combinational Therapies: Marketed

16. Emerging Therapies

16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.

16.2. Umbralisib: TG Therapeutics

16.2.4. Safety and Efficacy

16.3. ME-401: MEI Pharma

16.4. Odronextamab: Regeneron Pharmaceuticals

16.5. Parsaclisib: Incyte Corporation

16.6. Kymriah: Novartis

16.7. Yescarta: Kite Pharma

16.8. Nivolumab: Bristol-Myers Squibb

16.9. Ixazomib – Takeda Oncology

17. Emerging Combinational Therapies

17.1. Ibrutinib + Rituximab

17.2. Umbralisib + Ublituximab + Bendamustine

17.3. Zanubrutinib + Obinutuzumab

18. Other Promising Therapies

19. Follicular Lymphoma: Seven Major Market Analysis

20. Market Outlook

21. Market Drivers

22. Market Barriers

23. Market Access and Reimbursement

24. Appendix

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

Request sample pages for more information on Follicular Lymphoma Market Size

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/